ARCHIVES

Phase IIb Trial of Vintafolide-Docetaxel Combination Meets Primary Endpoint of Progression-Free Survival

This article is from The Cancer Letter archive.

Vol. 37 No. 3 | March 28, 2014

Download PDF Visit The Full Archive

Related Articles

Fourteen Immunology RFPs Announced, NCI will Have Eight More Immunodiagnosis; $43 Million Budgeted

September 6, 1974

ASCO Is a Society In Transition, Growth; Major changes over Past Year

May 24, 1996

James Abbruzzese Moves to Duke Cancer Institute

September 27, 2013

Common Chemotherapy Fertilizes Marrow Before Tumors Take Root

May 25, 2012

Physicians Accept Plans by City of Hope to Pay for Services Through New Foundation

June 3, 2011

In Brief: Columbia University Double Lab Space; GM Cancer Awards to Suit, Folkman, Nurse

June 6, 1997